In mouse models, co-injection of Nrf2-deficient PSCs with KPC mouse-derived pancreatic cancer cells resulted in the formation of smaller subcutaneous tumors compared to wild-type PSC co-injections (55). This evidence concerns the gene NFE2L2 and pancreatic neoplasm.